Nicholas Investment Partners LP Makes New Investment in Fulcrum Therapeutics, Inc. $FULC

Nicholas Investment Partners LP purchased a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the 4th quarter, Holdings Channel.com reports. The fund purchased 182,961 shares of the company’s stock, valued at approximately $2,069,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. First Turn Management LLC bought a new stake in Fulcrum Therapeutics during the fourth quarter worth $21,406,000. Entropy Technologies LP bought a new stake in Fulcrum Therapeutics during the fourth quarter worth $136,000. Barclays PLC raised its position in Fulcrum Therapeutics by 47.9% during the fourth quarter. Barclays PLC now owns 132,541 shares of the company’s stock worth $1,499,000 after acquiring an additional 42,925 shares in the last quarter. Marshall Wace LLP bought a new stake in Fulcrum Therapeutics during the fourth quarter worth $1,164,000. Finally, Walleye Capital LLC bought a new stake in Fulcrum Therapeutics during the fourth quarter worth $1,226,000. 89.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Wall Street Zen raised shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. Truist Financial lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a research report on Tuesday, June 2nd. Jefferies Financial Group set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Tuesday, June 2nd. Leerink Partners lowered shares of Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 price objective on the stock. in a research report on Tuesday, June 2nd. Finally, HC Wainwright lowered shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, Fulcrum Therapeutics presently has a consensus rating of “Reduce” and a consensus target price of $8.20.

Fulcrum Therapeutics Stock Down 2.8%

Shares of Fulcrum Therapeutics stock opened at $3.45 on Friday. The company has a market capitalization of $229.87 million, a price-to-earnings ratio of -3.00 and a beta of 2.93. Fulcrum Therapeutics, Inc. has a 12-month low of $2.83 and a 12-month high of $15.74. The firm’s 50-day moving average price is $6.59 and its two-hundred day moving average price is $8.82.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. On average, sell-side analysts expect that Fulcrum Therapeutics, Inc. will post -0.76 earnings per share for the current year.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.